Erasca (ERAS) Competitors $1.39 -0.03 (-1.77%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 08/1/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. OCUL, KNSA, APGE, ARQT, IMCR, SPRY, TARS, ADPT, SDGR, and JANXShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals International (KNSA), Apogee Therapeutics (APGE), Arcutis Biotherapeutics (ARQT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Tarsus Pharmaceuticals (TARS), Adaptive Biotechnologies (ADPT), Schrodinger (SDGR), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Its Competitors Ocular Therapeutix Kiniksa Pharmaceuticals International Apogee Therapeutics Arcutis Biotherapeutics Immunocore ARS Pharmaceuticals Tarsus Pharmaceuticals Adaptive Biotechnologies Schrodinger Janux Therapeutics Ocular Therapeutix (NASDAQ:OCUL) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Is OCUL or ERAS more profitable? Erasca has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -323.09%. Erasca's return on equity of -36.56% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-323.09% -59.92% -41.98% Erasca N/A -36.56%-31.08% Which has more risk and volatility, OCUL or ERAS? Ocular Therapeutix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Which has preferable valuation & earnings, OCUL or ERAS? Erasca has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M29.80-$193.51M-$1.15-10.37ErascaN/AN/A-$161.65M-$0.62-2.24 Does the media refer more to OCUL or ERAS? In the previous week, Ocular Therapeutix had 2 more articles in the media than Erasca. MarketBeat recorded 3 mentions for Ocular Therapeutix and 1 mentions for Erasca. Ocular Therapeutix's average media sentiment score of 0.46 beat Erasca's score of 0.15 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in OCUL or ERAS? 59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 14.4% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate OCUL or ERAS? Ocular Therapeutix presently has a consensus target price of $17.33, suggesting a potential upside of 45.41%. Erasca has a consensus target price of $4.57, suggesting a potential upside of 228.88%. Given Erasca's higher probable upside, analysts plainly believe Erasca is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Erasca 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryErasca beats Ocular Therapeutix on 10 of the 14 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$400.85M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-2.2417.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book0.938.508.275.54Net Income-$161.65M-$55.06M$3.25B$259.28M7 Day Performance-20.11%-3.99%-3.70%-4.64%1 Month Performance-4.14%9.58%4.34%4.41%1 Year Performance-49.18%6.70%25.90%17.95% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.0736 of 5 stars$1.39-1.8%$4.57+228.9%-54.7%$400.85MN/A-2.24120News CoverageGap DownOCULOcular Therapeutix3.6107 of 5 stars$12.08-1.1%$17.33+43.5%+47.7%$1.95B$63.72M-10.50230Upcoming EarningsKNSAKiniksa Pharmaceuticals International3.1521 of 5 stars$27.04+2.7%$39.67+46.7%+24.1%$1.92B$423.24M-108.16220News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAPGEApogee Therapeutics2.4749 of 5 stars$39.66-2.8%$99.00+149.6%-17.5%$1.88BN/A-11.0291Positive NewsARQTArcutis Biotherapeutics2.7194 of 5 stars$14.96+0.7%$19.40+29.7%+50.7%$1.77B$196.54M-14.38150News CoverageUpcoming EarningsIMCRImmunocore1.7414 of 5 stars$33.94-3.5%$58.89+73.5%-16.7%$1.77B$310.20M-78.93320News CoverageUpcoming EarningsSPRYARS Pharmaceuticals3.204 of 5 stars$18.35+2.7%$31.00+68.9%+63.8%$1.76B$89.15M-114.6890Upcoming EarningsTARSTarsus Pharmaceuticals2.5317 of 5 stars$41.75+0.6%$66.67+59.7%+74.2%$1.74B$182.95M-15.2950Positive NewsUpcoming EarningsADPTAdaptive Biotechnologies3.0058 of 5 stars$10.61-1.3%$10.57-0.4%+132.1%$1.63B$178.96M-11.05790Positive NewsUpcoming EarningsGap DownSDGRSchrodinger2.5882 of 5 stars$22.39+0.7%$32.75+46.3%-13.6%$1.63B$207.54M-8.51790Positive NewsUpcoming EarningsGap DownJANXJanux Therapeutics2.4078 of 5 stars$25.55-1.6%$91.89+259.6%-43.2%$1.54B$10.59M-18.7930Upcoming Earnings Related Companies and Tools Related Companies Ocular Therapeutix Alternatives Kiniksa Pharmaceuticals International Alternatives Apogee Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Immunocore Alternatives ARS Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Schrodinger Alternatives Janux Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
